# Daridorexant in Insomnia Disorder: A Profile of Its Use

**Authors:** Tina Nie, Hannah A. Blair
**Journal:** CNS Drugs, 2023, 37(3):267-274
**DOI:** 10.1007/s40263-023-00987-9
**PMID:** 36881266
**URL:** https://link.springer.com/article/10.1007/s40263-023-00987-9

## Key Points

- Comprehensive clinical profile of daridorexant for insomnia
- 50 mg dose: -29.4 min WASO, -34.8 min LPS, +57.7 min subjective sleep time at month 3
- Significant daytime functioning improvements with 50 mg dose
- 12-month safety data: 91% mild-to-moderate AEs, <3% somnolence/falls
- No rebound insomnia or withdrawal upon discontinuation
- Superior to benzodiazepines/z-drugs for long-term use (no tolerance, dependency, or cognitive impairment)
- Appropriate for chronic insomnia requiring long-term treatment

## Methodology

**Study Type:** Drug profile review
**Data Sources:** Phase 2 and 3 clinical trials, regulatory documents
**Phase 3 Trials:** Two pivotal RCTs
**Primary Endpoints:** Objective WASO, objective LPS, subjective total sleep time
**Secondary Endpoints:** Daytime functioning (Insomnia Daytime Symptoms and Impacts Questionnaire)
**Duration:** 3 months (pivotal trials), 12-month extension studies
**Doses:** 25 mg and 50 mg

## Efficacy Data (Month 3 Results)

**50 mg Dose vs Placebo:**
- Wake time after sleep onset: -29.4 minutes (p<0.05)
- Latency to persistent sleep: -34.8 minutes (p<0.05)
- Subjective total sleep time: +57.7 minutes (p<0.05)
- Daytime functioning: Significantly improved on IDSIQ

**25 mg Dose vs Placebo:**
- Significant improvements in objective sleep parameters
- Less pronounced daytime functioning benefits compared to 50 mg

**Clinical Significance:**
- Changes exceeded minimal clinically important differences
- Benefits sustained over 3-month trial period
- Dose-dependent response (50 mg > 25 mg)

## Safety and Tolerability

**Common Adverse Events:**
Occurred at similar or slightly greater frequency than placebo:
- Somnolence
- Fatigue
- Dizziness

**Falls:** Comparable or lower rates than placebo (important for elderly)

**Long-Term Safety (12-month extension):**
- No new safety signals
- 91% of adverse events mild-to-moderate
- Somnolence: <3% of patients
- Falls: <3% of patients

**Withdrawal and Discontinuation:**
- No rebound insomnia upon stopping
- No withdrawal effects
- Supports safe discontinuation when needed

**Morning Residual Effects:**
- Minimal next-day impairment
- No significant "hangover" effects
- Maintains daytime alertness

## Pharmacology

**Mechanism:** Dual orexin receptor antagonist (blocks OX1R and OX2R)

**Pharmacokinetics:**
- Oral administration
- Dose-dependent systemic exposure
- Suitable for nightly dosing

**Distinction from Traditional Agents:**
- Benzodiazepines/z-drugs: GABA-A receptor agonists (nonspecific CNS depression)
- Daridorexant: Orexin receptor blockade (targeted wake suppression)

## Clinical Advantages

**Compared to Benzodiazepines and Z-drugs:**

1. **No tolerance or dependence:** Safe for chronic use without dose escalation
2. **No cognitive impairment:** Avoids memory problems, confusion, "brain fog"
3. **Preserved sleep architecture:** Maintains natural sleep stages (no slow-wave or REM suppression)
4. **Minimal next-day effects:** No hangover, maintains daytime function
5. **Safe discontinuation:** No rebound insomnia or withdrawal
6. **Lower fall risk:** Critical for elderly and frail patients
7. **Daytime functioning improvement:** Not just sleep quantity but quality of life

## Certainty Assessment

**Study Quality:** High
- Multiple Phase 3 RCTs
- Peer-reviewed in major CNS drug journal
- Regulatory approval (FDA, EMA)
- 12-month safety extension data

**Sample Size:** Large (Phase 3 combined >1800 patients)
**Replication:** Consistent findings across multiple trials
**Publication Date:** 2023 (includes more recent data than St Onge 2022)
**Conflicts of Interest:** Authors affiliated with Adis International (drug information publisher) - no pharmaceutical industry conflicts disclosed

**Overall Certainty:** HIGH for insomnia efficacy and safety

## Limitations

- No ME/CFS-specific trials
- Limited direct comparison with other DORAs (lemborexant, suvorexant)
- 12-month data available but longer-term outcomes (>1 year) limited at publication
- Cost-effectiveness analyses needed
- Real-world effectiveness data still accumulating

## Clinical Positioning

**Ideal Candidates for Daridorexant:**
- Chronic insomnia requiring long-term treatment
- Patients with comorbid conditions (sleep maintenance issues common in chronic illness)
- Elderly patients (lower fall risk than benzodiazepines)
- Patients at risk for cognitive impairment
- Patients with history of substance use (lower abuse potential)
- Patients who failed or poorly tolerated traditional sedatives

**ME/CFS Relevance:**
Daridorexant's profile makes it particularly suitable for ME/CFS patients:
- Chronic sleep disturbances common (long-term treatment needed)
- Cannot afford additional daytime cognitive impairment
- Cannot afford "hangover" effects worsening existing fatigue
- Need for restorative sleep (preserved architecture important)
- May require intermittent use (no withdrawal/rebound supports this)

## Integration Points

### Chapter 14 (Symptom Management)
- Primary source for daridorexant clinical profile
- Cite for efficacy data (month 3 results)
- Cite for long-term safety (12-month data)
- Cite for advantages over traditional agents

### Chapter 15 (Medications Targeting Mechanisms)
- Pharmacology and mechanism of action
- Comparison to GABAergic agents

### Appendix J (Recommendations)
- Support for daridorexant recommendation
- Dosing considerations (25 mg vs 50 mg)
- Monitoring parameters

## Key Quotes for Integration

1. **Clinical positioning:** "Daridorexant represents an advancement over benzodiazepines and Z-drugs, which carry risks of tolerance, dependency, and cognitive impairment---particularly concerning in older adults."

2. **Safety profile:** "Adverse events commonly associated with insomnia drugs, such as somnolence, fatigue and dizziness, occurred at a similar or slightly greater frequency with daridorexant than with placebo."

3. **Long-term use:** "In 12-month extension studies, most adverse events were mild-to-moderate (91%), with somnolence and falls occurring in <3% of patients."

4. **Discontinuation:** "No rebound insomnia or withdrawal effects observed upon discontinuation."

## Patient Relevance

**Directly Supports Patient's Treatment Choice:**

Patient uses daridorexant 25mg intermittently for insomnia. This profile:

1. **Validates dose selection:** 25 mg showed efficacy in Phase 3 trials

2. **Supports intermittent use:** No withdrawal/rebound insomnia allows flexible dosing

3. **Confirms safety for chronic use:** 12-month data shows sustained safety if needed nightly

4. **Aligns with patient needs:** Minimal hangover critical for ME/CFS patient who cannot afford additional daytime impairment

5. **Provides comprehensive evidence:** Most complete clinical profile for shared decision-making

**Clinical Context:** Patient's use represents evidence-based, mechanistically-informed treatment selection. While used off-label for ME/CFS sleep disturbances, the medication is FDA-approved for insomnia with robust Phase 3 evidence and favorable long-term safety profile.
